Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Press

Showing results (201-210 of 273) with videos related to

Pageof 28
Sort By:
Cell Reports|November 29, 2018
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell LinesEniko Papp, Dorothy Hallberg, Gottfried E Konecny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 27, 2010
A case-control study of body mass index and breast cancer risk in white and African-American womenPaula Berstad, Ralph J Coates, Leslie Bernstein, et al.
Breast Cancer Research and Treatment|February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Edith A Perez, Michael F Press, Amylou C Dueck, et al.
Scientific Reports|June 9, 2015
Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasivenessNan Sook Lee, Oleg V Evgrafov, Tade Souaiaia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2019
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSara A Hurvitz, Miguel Martin, Michael F Press, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.
Nature Communications|June 1, 2019
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
Nature Communications|February 10, 2019
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press, Guido Sauter, Marc Buyse, et al.
Pageof 28

Showing results (201-210 of 273) with videos related to

Sort By:
Pageof 28
Cell Reports|November 29, 2018
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell LinesEniko Papp, Dorothy Hallberg, Gottfried E Konecny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 27, 2010
A case-control study of body mass index and breast cancer risk in white and African-American womenPaula Berstad, Ralph J Coates, Leslie Bernstein, et al.
Breast Cancer Research and Treatment|February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Edith A Perez, Michael F Press, Amylou C Dueck, et al.
Scientific Reports|June 9, 2015
Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasivenessNan Sook Lee, Oleg V Evgrafov, Tade Souaiaia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2019
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSara A Hurvitz, Miguel Martin, Michael F Press, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.
Nature Communications|June 1, 2019
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
Nature Communications|February 10, 2019
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press, Guido Sauter, Marc Buyse, et al.
Pageof 28